Genetic analysis of familial forms of Alzheimer's disease (AD) causally links the proteolytic processing of the amyloid precursor protein (APP) and AD. However, the specific type of amyloid and mechanisms of amyloid pathogenesis remain unclear. We conducted a detailed analysis of intracellular amyloid with an aggregation specific conformation dependent monoclonal antibody, M78, raised against fibrillar Aß42. M78 immunoreactivity colocalizes with Aß and the carboxyl terminus of APP (APP-CTF) immunoreactivities in perinuclear compartments at intermediate times in 10 month 3XTg-AD mice, indicating that this represents misfolded and aggregated protein rather than normally folded APP. At 12 months, M78 immunoreactivity also accumulates in the nucleus. Neuritic plaques at 12 months display the same spatial organization of centrally colocalized M78, diffuse chromatin and neuronal nuclear NeuN staining surrounded by peripheral M78 and APP-CTF immunoreactivity as observed in neurons, indicating that neuritic plaques arise from degenerating neurons with intracellular amyloid immunoreactivity. The same staining pattern was observed in neuritic plaques in human AD brains, showing elevated intracellular M78 immunoreactivity at intermediate stages of amyloid pathology (Braak A and B) compared to no amyloid pathology and late stage amyloid pathology (Braak 0 and C, respectively). These results indicate that intraneuronal protein aggregation and amyloid accumulation is an early event in AD and that neuritic plaques are initiated by the degeneration and death of neurons by a mechanism that may be related to the formation of extracellular traps by neutrophils.
Introduction
Alzheimer's disease (AD) has traditionally been defined by the presence of extracellular plaques containing aggregated amyloid ß (Aß) and intracellular tangles containing aggregated tau. However, accumulation of aggregated Aß in plaques does not correlate well with disease and many individuals with large amounts of amyloid deposits are not demented (Terry, 1996) . This suggests that some form of unseen Aß which may accumulate prior to extracellular plaque deposition is more closely associated with pathogenesis. Soon after the discovery of Aß, it was observed that APP and Aß immunoreactivity accumulates in the perinuclear area of a subset of neurons and in the corona of dystrophic neurites surrounding neuritic plaques and it was proposed that this APP represents the penultimate source of Aß accumulating in the core of the neuritic plaques (Selkoe et al., 1988; Grundke-Iqbal et al., 1989; Ikeda et al., 1989; Perry et al., 1989; Stern et al., 1989; Arai et al., 1990; Cummings et al., 1992) . However, with the discovery of soluble secreted Aß, this interpretation fell out of favor (Joachim et al., 1991) . Many transgenic animal models of AD exhibit intracellular Aß and APP immunoreactivity (reviewed in (Wirths and Bayer, 2012) ) that precedes cognitive decline and amyloid deposition or that is associated with neuronal loss (Schmitz et al., 2004) and synaptic dysfunction (Oddo et al., 2003) . Many of the accumulating immunoreactive 
